IMC-002 (IMM0306), a bispecific CD20×CD47 fusion protein, demonstrates improvements in active Systemic Lupus Erythematosus patients in a phase Ib/II study

The latest data demonstrate that the combination regimen delivers high response rates, durable progression-free survival benefits, and a favorable safety profile in patients with R/R marginal zone lymphoma (MZL) and R/R follicular lymphoma (FL), offering a highly promising new therapeutic option for patients with R/R indolent B-cell lymphomas. The Phase II clinical study is ongoing.

The study is designed to assess the preliminary anti-tumor efficacy and safety of the combination in this patient population.

These achievements mark significant progress in the program's advancement toward patient validation.

This milestone represents a key step forward in the global clinical development of IMM0306 across autoimmune diseases, bringing a potential breakthrough therapeutic option one step closer to millions of SLE patients worldwide.